Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly FCF Margin came in at 237.95% in Q1 2026, down 10620.0% YoY from N/an in Q1 2025, and down 66.66% on a QoQ basis from 142.78% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of FCF Margin data on file, last reported at 237.95% in Q1 2026.
- Quarterly FCF Margin fell 10620.0% year-over-year to 237.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123.62% (up 2441.0% YoY) and the FY2025 annual result came in at 105.04%, up 6327.0% from the prior year.
- FCF Margin eased to 237.95% in Q1 2026, from 142.78% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 10.5% in Q1 2022 to a low of 252.92% in Q1 2024.
- A 5-year average of 123.16% and a median of 115.52% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 14839 bps — and 2024, when it sank 19952 bps.
- Tracing DNA's FCF Margin over 5 years: stood at 149.36% in 2022, then soared by 74 bps to 39.45% in 2023, then tumbled by 506 bps to 238.97% in 2024, then soared by 40 bps to 142.78% in 2025, then plunged by 67 bps to 237.95% in 2026.
- The last three FCF Margin figures came in at 237.95% (Q1 2026), 142.78% (Q4 2025), and 100.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -232.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -232.65% |
| Mar 31, 2026 | -237.95% |
| Dec 31, 2025 | -142.78% |
| Sep 30, 2025 | -100.78% |
| Jun 30, 2025 | -83.72% |
| Mar 31, 2025 | -131.76% |
| Dec 31, 2024 | -238.97% |
| Sep 30, 2024 | -115.52% |
| Jun 30, 2024 | -139.69% |
| Mar 31, 2024 | -252.92% |
| Dec 31, 2023 | -39.45% |
| Sep 30, 2023 | -78.13% |
| Jun 30, 2023 | -108.07% |
| Mar 31, 2023 | -136.34% |
| Dec 31, 2022 | -149.36% |
| Sep 30, 2022 | -57.14% |
| Jun 30, 2022 | -70.56% |
| Mar 31, 2022 | -10.50% |
| Dec 31, 2021 | -77.22% |
| Sep 30, 2021 | -13.75% |